drugset / Trial / NCT00827177
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.
Timeline
- Start
- 2009-09
- Primary completion
- 2012-09
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 200 mg | — |
| Subject | Sorafenib | Small molecule | 400 mg | — |
| Subject | Tivantinib | Small molecule | 240 mg | Oral |
| Subject | Tivantinib | Small molecule | 360 mg | Oral |